Shilpa Biologicals Private Limited (SBPL), established in 2020 and headquartered in Dharwad, Karnataka, India, is a biopharmaceutical company specializing in the development and manufacture of high-quality, affordable biologics. SBPL offers services encompassing clone development, process development, analytical and microbiological testing, and large-scale manufacturing. The company's capabilities include both microbial and mammalian host systems, with significant manufacturing capacities: microbial fermentation ranging from 200 L to 55,000 L and mammalian cell culture ranging from 50 L to 2,000 L. In 2025, SBPL launched a "hybrid CDMO" model, providing both traditional outsourcing services and commercially ready, off-the-shelf novel formulations for business-to-business licensing, focusing especially on oncology therapeutics.